Rehmannioside A
Based on 1 publication(s) in Google Scholar
Rehmannioside A is a compound that can be isolated from Rehmanniae radix. Rehmannioside A is an inhibitor of CYP3A4, 2C9 and 2D6, with IC50 values of 10.08, 12.62 and 16.43 μM, respectively. Rehmannioside A has anti-inflammatory, antioxidant, anti-apoptosis, anti-ferroptosis, cognitive improvement and neuroprotective activities. Rehmannioside A can be used for the research of nervous system and inflammation-related diseases.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.95%
- CAS 番号: 81720-05-0
- 分子式: C21H32O15
- 分子量:524.47
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
MedChemExpress(MCE)の使用を引用している文献 Rehmannioside A
MoreMEK アイソフォーム固有の製品をすべて表示
More
生物活性
|
CYP2C9 12.62 μM (IC50) |
CYP3A4 10.08 μM (IC50) |
CYP2D6 16.43 μM (IC50) |
iNOS |
Bcl-2 |
COX-2 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A2780 | IC50 |
>10 μM
Compound: 16
|
Cytotoxicity against human A2780 cells by MTT assay
Cytotoxicity against human A2780 cells by MTT assay
|
[PMID: 26859776] |
| A549 | IC50 |
>10 μM
Compound: 16
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 26859776] |
| Bel-7402 | IC50 |
>10 μM
Compound: 16
|
Cytotoxicity against human Bel7402 cells by MTT assay
Cytotoxicity against human Bel7402 cells by MTT assay
|
[PMID: 26859776] |
| BGC-823 | IC50 |
>10 μM
Compound: 16
|
Cytotoxicity against human BGC823 cells by MTT assay
Cytotoxicity against human BGC823 cells by MTT assay
|
[PMID: 26859776] |
| HT-29 | IC50 |
>10 μM
Compound: 16
|
Cytotoxicity against human HT-29 cells by MTT assay
Cytotoxicity against human HT-29 cells by MTT assay
|
[PMID: 26859776] |
Rehmannioside A (0-100 μM; 24 h) can improve high-glucose-induced decrease in cell viability and inhibit apoptosis and oxidative stress in HK2 cells (increasing the activities of SOD and CAT, reducing the levels of MDA, and decreasing LDH release and ROS production). The mechanism is involved in the inhibition of p38 MAPK and ERK1/2 phosphorylation[1].
Rehmannioside A (0-80 μM; 48 h) inhibits the release of pro-inflammatory mediators and promotes M2 polarization in LPS (HY-D1056)-treated BV2 cells. The mechanism is related to the inhibition of NF-κB and MEK signaling pathways[2].
Rehmannioside A (80 μM; 48 h) reduces neuronal apoptosis and restores the expression of anti-apoptotic protein Bcl-2 in the co-culture system of PC12 and BV2 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HK2 cells treated high-glucose
-
Concentration:20, 40 and 80 μM
-
Incubation Time:24 h
-
Result:Significantly inhibited the levels of BAX and cleaved PARP proteins and increased Bcl-2 levels.
-
Cell Line:BV2 cells treated LPS (HY-D1056)
-
Concentration:0, 20, 40 and 80 μM
-
Incubation Time:Pretreated with 24 h, then co-incubation for 24 h
-
Result:Inhibited the levels of iNOS and COX-2.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female SD rats (200-250 g) with spinal cord injury[2]
-
Dosage:80 mg/kg
-
Administration:Intraperitoneal injection; 28 days
-
Result:Significantly improved the behavioural and histological indices.
Promoted M2 microglial polarization.
Alleviated neuronal apoptosis.
Increased motor function recovery.
化学情報
-
CAS 番号 81720-05-0
-
性状 Solid
-
分子量 524.47
-
分子式 C21H32O15
-
Color White to off-white
-
SMILES
OC[C@@]1([C@]([C@@H]2O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]([C@H]3O)CO[C@H]([C@@H]([C@H]4O)O)O[C@@H]([C@@H]4O)CO)([H])[C@](C=CO2)([H])[C@@H]5O)[C@@]5([H])O1
-
Structure Classification
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
J Ethnopharmacol
Radix Rehmanniae Praeparata promoted zebrafish fin regeneration through aryl hydrocarbon receptor-dependent autophagy. [Abstract]2024 Sep 15:331:118272. PMID: 38710459
溶剤 & 溶解度
H2O : ≥ 100 mg/mL (190.67 mM)
DMSO : 50 mg/mL (95.33 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.25 mg/mL (2.38 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.25 mg/mL (2.38 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
純度とドキュメンテーション
-
データシート (285 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
取扱説明書 (2659 KB)
参考文献
[2]. Xiao S, et al. Rea regulates microglial polarization and attenuates neuronal apoptosis via inhibition of the NF-κB and MAPK signalings for spinal cord injury repair. J Cell Mol Med. 2021 Feb;25(3):1371-1382. [Content Brief]
[3]. Wang C,et al. Rehmannioside A inhibits the activity of CYP3A4, 2C9 and 2D6 in vitro. Xenobiotica. 2024 Apr;54(4):195-200. [Content Brief]
[4]. Fu C, et al. Rehmannioside A improves cognitive impairment and alleviates ferroptosis via activating PI3K/AKT/Nrf2 and SLC7A11/GPX4 signaling pathway after ischemia. J Ethnopharmacol. 2022 May 10;289:115021. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / H2O | 1 mM | 1.9067 mL | 9.5334 mL | 19.0669 mL | 47.6672 mL |
| 5 mM | 0.3813 mL | 1.9067 mL | 3.8134 mL | 9.5334 mL | |
| 10 mM | 0.1907 mL | 0.9533 mL | 1.9067 mL | 4.7667 mL | |
| 15 mM | 0.1271 mL | 0.6356 mL | 1.2711 mL | 3.1778 mL | |
| 20 mM | 0.0953 mL | 0.4767 mL | 0.9533 mL | 2.3834 mL | |
| 25 mM | 0.0763 mL | 0.3813 mL | 0.7627 mL | 1.9067 mL | |
| 30 mM | 0.0636 mL | 0.3178 mL | 0.6356 mL | 1.5889 mL | |
| 40 mM | 0.0477 mL | 0.2383 mL | 0.4767 mL | 1.1917 mL | |
| 50 mM | 0.0381 mL | 0.1907 mL | 0.3813 mL | 0.9533 mL | |
| 60 mM | 0.0318 mL | 0.1589 mL | 0.3178 mL | 0.7945 mL | |
| 80 mM | 0.0238 mL | 0.1192 mL | 0.2383 mL | 0.5958 mL | |
| H2O | 100 mM | 0.0191 mL | 0.0953 mL | 0.1907 mL | 0.4767 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.